An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity-Reference-Cited by-同舟云学术

An Overview of the Strategies to Boost SARS-CoV-2-Specific Immunity in People with Inborn Errors of Immunity

Published:2024-06-18 Issue:6 Volume:12 Page:675
ISSN:2076-393X
Container-title:Vaccines
language:en
Short-container-title:Vaccines

Author:

Chang-Rabley Emma¹,van Zelm Menno C.²³⁴^ORCID,Ricotta Emily E.¹⁵^ORCID,Edwards Emily S. J.²³^ORCID

Affiliation:

1. The Laboratory of Clinical Immunology and Microbiology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA

2. Allergy and Clinical Immunology Laboratory, Department of Immunology, Central Clinical School, Monash University, Melbourne, VIC 3800, Australia

3. The Jeffrey Modell Diagnostic and Research Centre for Primary Immunodeficiencies in Melbourne, Melbourne, VIC 3000, Australia

4. Department of Immunology, Erasmus MC, University Medical Center, 3015 GD Rotterdam, The Netherlands

5. Department of Preventive Medicine and Biostatistics, Uniform Services University of the Health Sciences, Bethesda, MD 20814, USA

Abstract

The SARS-CoV-2 pandemic has heightened concerns about immunological protection, especially for individuals with inborn errors of immunity (IEI). While COVID-19 vaccines elicit strong immune responses in healthy individuals, their effectiveness in IEI patients remains unclear, particularly against new viral variants and vaccine formulations. This uncertainty has led to anxiety, prolonged self-isolation, and repeated vaccinations with uncertain benefits among IEI patients. Despite some level of immune response from vaccination, the definition of protective immunity in IEI individuals is still unknown. Given their susceptibility to severe COVID-19, strategies such as immunoglobulin replacement therapy (IgRT) and monoclonal antibodies have been employed to provide passive immunity, and protection against both current and emerging variants. This review examines the efficacy of COVID-19 vaccines and antibody-based therapies in IEI patients, their capacity to recognize viral variants, and the necessary advances required for the ongoing protection of people with IEIs.

Funder

Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, USA

Australasia (AIFA) Primary Immunodeficiency Clinical Research Grant

Australasian Government Medical Research Future Fund

Jeffrey Modell Foundation

Publisher

MDPI AG

Link

https://www.mdpi.com/2076-393X/12/6/675/pdf

Reference227 articles.

1. World Health Organization (2023). WHO Coronavirus (COVID-19) Dashboard, World Health Organization.

2. (2023, January 05). COVID-19 Data Explorer—Our World in Data. Available online: https://ourworldindata.org/explorers/coronavirus-data-explorer?zoomToSelection=true&time=2020-03-01..latest&facet=none&pickerSort=asc&pickerMetric=location&Metric=Case+fatality+rate&Interval=7-day+rolling+average&Relative+to+Population=true&Color+by+test+positivity=false&country=JPN~USA~GBR~ITA~DEU~FRA~CAN.

3. COVID Human Genetic Effort consortium Impact of SARS-CoV-2 infection and COVID-19 on patients with inborn errors of immunity;Tangye;J. Allergy Clin. Immunol.,2023

4. Human Coronavirus NL63 Infection and Other Coronavirus Infections in Children Hospitalized with Acute Respiratory Disease in Hong Kong, China;Chiu;Clin. Infect. Dis.,2005

5. New insights into human immune memory from SARS-CoV-2 infection and vaccination;Hartley;Allergy,2022